HealthCare Global Enterprises Ltd. (HCG) AI Stock Analysis

• Market Cap: ₹103.33B
• Dividend Yield: N/A
• Average Volume (3M): 18.12K
• Price to Earnings (P/E): 275.5
• Beta (1Y): 0.40
• Revenue Growth: 16.85%
• EPS Growth: -29.57%
• Country: IN
• Employees: 6,150
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 0.40
• Shares Outstanding: 141,000,100
• 10 Day Avg. Volume: 16,611
• 30 Day Avg. Volume: 18,118
• PEG Ratio: -21.26
• Price to Book (P/B): 7.99
• Price to Sales (P/S): 3.32
• P/FCF Ratio: 68.08
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹621.50
• Price Target Upside: -15.19% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 2

• Rating: 61 Neutral
• Price Target: ₹653.00 ▼(-10.90% Downside)

The stock score is primarily driven by strong financial performance, characterized by revenue growth and profitability improvements. However, overvaluation concerns and technical indicators suggesting overbought conditions pose significant risks, balancing the overall score to a moderate level.

HealthCare Global Enterprises Ltd. Business Overview & Revenue Model

Company Description

HealthCare Global Enterprises Ltd. (HCG) is a prominent healthcare service provider based in India, specializing in oncology and other critical care services. The company operates a network of advanced cancer treatment centers and hospitals across various locations, focusing on providing comprehensive cancer care, including diagnosis, treatment, and rehabilitation. HCG is known for its innovative approaches in radiation therapy, chemotherapy, and surgical oncology, along with its commitment to research and clinical trials aimed at improving patient outcomes.

How the Company Makes Money

HCG generates revenue primarily through its healthcare services, including inpatient and outpatient treatments, surgeries, and specialized oncology services. Key revenue streams include payments from patients for treatments, consultations, and diagnostic services, as well as reimbursement from insurance companies and government health programs. Additionally, the company may earn income from partnerships with pharmaceutical firms for clinical trials and drug development, as well as from its research initiatives. HCG's strategic collaborations with healthcare providers and institutions further enhance its capabilities and market reach, contributing to its overall earnings.

HealthCare Global Enterprises Ltd. Financial Statement Overview

Summary

HealthCare Global Enterprises Ltd. has demonstrated strong revenue growth and improving profitability margins. However, the company faces challenges with decreasing net income and a leveraged balance sheet, indicating potential financial stability risks.

Income Statement

HealthCare Global Enterprises Ltd. has shown a strong revenue growth trajectory over the years. The company improved its revenue by 17.35% from 2024 to 2025. The gross profit margin stands at 52.11% and net profit margin at 2.00% for 2025, with a noticeable improvement in profitability metrics like EBIT and EBITDA margins, which are at 7.93% and 19.06% respectively. However, the net income has decreased compared to 2024, indicating potential operational challenges.

Balance Sheet

The company shows a moderately balanced financial structure with a debt-to-equity ratio of 1.99, indicating reliance on debt. The equity ratio at 26.02% reflects a reasonable level of equity financing. Return on Equity is low at 4.81%, suggesting limited profitability for equity holders. Overall, the balance sheet indicates a stable but leveraged position.

Cash Flow

HealthCare Global Enterprises Ltd. has demonstrated consistent positive operating cash flows, showing operational efficiency. The Operating Cash Flow to Net Income ratio is robust at 7.14, indicating strong cash flow generation relative to net income. Free Cash Flow has shown a growth of 9.39% from the previous year, reflecting healthy cash management. However, the Free Cash Flow to Net Income ratio at 2.44 highlights potential concerns in cash flow efficiency.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	23.10B	22.23B	19.12B	16.94B	13.98B	10.13B
Gross Profit	12.16B	11.91B	10.48B	9.20B	7.52B	5.27B
EBITDA	3.47B	3.13B	2.67B	2.37B	1.78B	656.22M
Net Income	370.80M	444.10M	481.55M	293.49M	537.33M	-1.93B
Balance Sheet
Total Assets	0.00	35.43B	27.07B	23.16B	22.20B	20.36B
Cash, Cash Equivalents and Short-Term Investments	3.48B	3.53B	3.03B	1.97B	2.04B	1.66B
Total Debt	0.00	18.37B	12.74B	9.01B	9.15B	9.78B
Total Liabilities	-9.90B	25.53B	18.42B	14.47B	13.36B	13.22B
Stockholders Equity	9.90B	9.22B	8.26B	8.61B	8.70B	6.97B
Cash Flow
Free Cash Flow	0.00	1.08B	988.99M	1.18B	1.49B	850.97M
Operating Cash Flow	0.00	3.17B	2.85B	2.52B	2.20B	1.21B
Investing Cash Flow	0.00	-4.88B	-2.26B	-1.33B	1.25B	-1.71B
Financing Cash Flow	0.00	-424.40M	-640.16M	-1.40B	-1.55B	1.12B

HealthCare Global Enterprises Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 732.85
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:HCG, the sentiment is Positive. The current price of 732.85 is above the 20-day moving average (MA) of 667.10, above the 50-day MA of 669.78, and above the 200-day MA of 570.99, indicating a bullish trend. The MACD of 12.81 indicates Negative momentum. The RSI at 71.64 is Negative, neither overbought nor oversold. The STOCH value of 81.96 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:HCG.

HealthCare Global Enterprises Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ASTERDM	77 Outperform	₹364.14B	110.81	―	0.71%	-53.19%	-94.01%
FORTIS	75 Outperform	₹819.24B	94.33	―	0.09%	14.04%	32.99%
MEDANTA	71 Outperform	₹374.96B	70.14	―	0.04%	15.42%	10.66%
NH	67 Neutral	₹358.95B	45.49	―	0.26%	12.09%	-2.79%
MAXHEALTH	64 Neutral	₹1.17T	101.85	―	0.12%	32.65%	8.86%
HCG	61 Neutral	₹103.33B	275.51	―	―	16.85%	-29.57%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%